Aardvark Therapeutics, Inc.
AARD
$6.41
-$0.16-2.44%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.63M | 5.90M | 4.41M | 3.97M | 2.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.08M | 22.46M | 18.70M | 17.70M | 15.85M |
| Operating Income | -15.08M | -22.46M | -18.70M | -17.70M | -15.85M |
| Income Before Tax | -14.39M | -21.59M | -17.60M | -16.32M | -14.37M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.39M | -21.59M | -17.60M | -16.32M | -14.37M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.39M | -21.59M | -17.60M | -16.32M | -14.37M |
| EBIT | -15.08M | -22.46M | -18.70M | -17.70M | -15.85M |
| EBITDA | -15.07M | -22.45M | -18.69M | -17.69M | -15.84M |
| EPS Basic | -0.66 | -0.99 | -0.81 | -0.75 | -0.66 |
| Normalized Basic EPS | -0.41 | -0.62 | -0.50 | -0.47 | -0.41 |
| EPS Diluted | -0.66 | -0.99 | -0.81 | -0.75 | -0.66 |
| Normalized Diluted EPS | -0.41 | -0.62 | -0.50 | -0.47 | -0.41 |
| Average Basic Shares Outstanding | 21.85M | 21.82M | 21.78M | 21.71M | 21.69M |
| Average Diluted Shares Outstanding | 21.85M | 21.82M | 21.78M | 21.71M | 21.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |